Angiohematopoietic Progenitor Cells
A purified human cell population of subsets of angiohematopoietic progenitor cells, wherein the population is at least 94% pure and wherein the cells are selected with cell markers selected from the group of KDR, APLNR, VE-cadherin, PDGFRα, CD31, CD235a, CD73, CD43, and CD41a.
1 . A purified human cell population of hematovascular mesodermal precursors (Cell Population A), wherein the population is at least 94% pure and wherein the cells are characterized as VE-cadherin − , KDR bright , APLNR + , PDGFRα low− .
2 . The cell population of claim 1 , wherein the population expresses the gene for TRPA1 mechano- and chemoreceptor.
3 . The cell population of claim 1 , wherein the cells are capable of forming hematoendothelial colonies with at least 1 in 10 frequency.
4 . A purified human cell population of hemogenic endothelial progenitors (Cell Population D, VE-cadherin+,CD73−CD235a/CD43−); angiogenic hematopoietic progenitors (Cell Population E, VE-cadherin+CD235a/CD43+CD41a−) or non-hemogenic endothelial progenitors (Cell Population C, VE-cadherin+CD73+) wherein the cell population is at least 94% pure.
5 . The hemogenic endothelial cells of claim 4 , wherein the cells are CD117 intermediate .
6 . The angiogenic hematopoietic progenitor cells of claim 4 , wherein the cells are CD73−.
7 . The non-hemogenic endothelial progenitors cells of claim 4 wherein the cells are CD117 high and CD73+.
8 . A method of examining a drug for ability to modify cell differentiation, comprising the step of exposing at least one of the cell populations of claim 1 to a test drug and observing the effect of the drug on cell growth, differentiation, or viability.
9 . A method of examining a drug for ability to modify cell differentiation, comprising the step of exposing at least one of the cell populations of claim 4 to a test drug and observing the effect of the drug on cell growth, differentiation, or viability.
10 . A method of obtaining the cell populations of claim 1 comprising the steps of:
a) culturing pluripotent stem cells so that hematoendothelial differentiation occurs, and
b) sorting the cells by cell markers selected from the group consisting of KDR, APLNR, VE-cadherin, PDGFRα, CD31, CD235a, CD73, CD43, and CD41a such that a purified cell population of the cells of claim 1 is obtained.
11 . A method of obtaining the cell populations of claim 4 comprising the steps of:
a) culturing pluripotent stem cells so that hematoendothelial differentiation occurs, and
b) sorting the cells by cell markers selected from the group consisting of VE-cadherin, CD235a, CD73, CD43, and CD41a such that a purified cell population of at least one of the cell populations of claim 4 is obtained.
12 . A method of treating a patient, comprising the step of supplying at least one of the cell populations of claim 1 in a therapy selected from the group of bone marrow transplantation, blood transfusion, immunotherapy, treatment of cardiovascular diseases, treatment of ischemia, diabetic ulcers, regeneration of vasculature, and artificial tissue constructs.
13 . A method of treating a patient, comprising the step of supplying at least one of the cell populations of claim 4 in a therapy selected from the group of bone marrow transplantation, blood transfusion, immunotherapy, treatment of cardiovascular diseases, treatment of ischemia, diabetic ulcers, regeneration of vasculature, and artificial tissue constructs.
14 . A method of treating a patient in need of blood cell reconstitution and/or restoration of endothelial cell activity comprising the step of administering the cell population of claim 1 to a patient, wherein the cells will differentiate into blood cells or endothelial cells.
15 . A method of treating a patient in need of blood cell reconstitution and/or restoration of endothelial cell activity comprising the step of administering at least one of the cell populations of claim 4 to a patient, wherein the cells will differentiate into blood cells or endothelial cells.